Core Needle Biopsy of Breast Cancer Tumors Increases Distant Metastases in a Mouse Model

Neoplasia (United States)

Volumn 16, Issue 11, 2014, Pages 950-960

  Mathenge, Edward Gitau ^a   Dean, Cheryl Ann ^a   Clements, Derek ^a   Vaghar Kashani, Ahmad ^a   Photopoulos, Steffany ^a   Coyle, Krysta Mila ^a   Giacomantonio, Michael ^b   Malueth, Benjamin ^a   Nunokawa, Anna ^a   Jordan, Julie ^a   Lewis, John D ^c   Gujar, Shashi Ashok ^a,d   Marcato, Paola ^a   Lee, Patrick W K ^a   Giacomantonio, Carman Anthony ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b ST FRANCIS XAVIER UNIVERSITY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d IWK HEALTH CENTRE   (Canada)

Author keywords

Breast cancer; Core needle biopsy; Epithelial mesenchymal transition; Metastasis immunosuppression

Indexed keywords

CALGRANULIN A; CXCL2 CHEMOKINE; CYCLOOXYGENASE 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR SOX4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; LARGE CORE NEEDLE BIOPSY; LUNG METASTASIS; MACROPHAGE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84930277301     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.09.004     Document Type: Article

References (76)

1. Koka R, Ioffe OB Breast carcinoma: is molecular evaluation a necessary part of current pathological analysis?. Semin Diagn Pathol 2013, 30:321-328. 10.1053/j.semdp.2013.11.004.
2. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989, 81:1879-1886.
3. Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, Easton D, Forbes JF, Key T, Hankinson SE, et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 2007, 14:169-187. 10.1677/ERC-06-0045.
4. Jacobi CE, de Bock GH, Siegerink B, van Asperen CJ Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose?. Breast Cancer Res Treat 2009, 115:381-390. 10.1007/s10549-008-0070-x.
5. Wolf I, Ben-Baruch N, Shapira-Frommer R, Rizel S, Goldberg H, Yaal-Hahoshen N, Klein B, Geffen DB, Kaufman B Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study. Cancer 2008, 112:731-736. 10.1002/cncr.23225.
6. Gipponi M, Bassetti C, Canavese G, Catturich A, Di Somma C, Vecchio C, Nicolò G, Schenone F, Tomei D, Cafiero F Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients. J Surg Oncol 2004, 85:102-111. 10.1002/jso.20022.
7. Carter CL, Allen C, Henson DE Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63:181-187.
8. Breast Cancer Statistics & Survival Rates: Breast Cancer Cases/Deaths per Year (U.S. and World) http://www.imaginis.com/breast-health/breast-cancer-statistics-on-incidence-survival-and-screening-2.
9. Doberneck RC Breast biopsy: a study of cost-effectiveness. Ann Surg 1980, 192:152-156.
10. Duijm LE, Groenewoud JH, Roumen RM, de Koning HJ, Plaisier ML, Fracheboud J A decade of breast cancer screening in The Netherlands: trends in the preoperative diagnosis of breast cancer. Breast Cancer Res Treat 2007, 106:113-119. 10.1007/s10549-006-9468-5.
11. Holloway CM, Gagliardi AR Percutaneous needle biopsy for breast diagnosis: how do surgeons decide?. Ann Surg Oncol 2009, 16:1629-1636. 10.1245/s10434-009-0451-3.
12. Holloway CM, Saskin R, Brackstone M, Paszat L Variation in the use of percutaneous biopsy for diagnosis of breast abnormalities in Ontario. Ann Surg Oncol 2007, 14:2932-2939. 10.1245/s10434-007-9362-3.
13. Holloway CM, Saskin R, Paszat L Geographic variation and physician specialization in the use of percutaneous biopsy for breast cancer diagnosis. Can J Surg 2008, 51:453-463.
14. Breast Cancer Statistics at a Glance http://www.cancer.ca/en/cancer-information/cancer-101/cancer-statistics-at-a-glance/?region=ns.
15. Londero V, Zuiani C, Furlan A, Nori J, Bazzocchi M Role of ultrasound and sonographically guided core biopsy in the diagnostic evaluation of ductal carcinoma in situ (DCIS) of the breast. Radiol Med 2007, 112:863-876. 10.1007/s11547-007-0183-z.
16. Hemmer JM, Kelder JC, van Heesewijk HP Stereotactic large-core needle breast biopsy: analysis of pain and discomfort related to the biopsy procedure. Eur Radiol 2008, 18:351-354. 10.1007/s00330-007-0762-3.
17. Venkataraman S, Dialani V, Gilmore HL, Mehta TS Stereotactic core biopsy: comparison of 11 gauge with 8 gauge vacuum assisted breast biopsy. Eur J Radiol 2012, 81:2613-2619. 10.1016/j.ejrad.2011.10.027.
18. Philpotts LE Controversies in core-needle breast biopsy. Semin Roentgenol 2001, 36:270-283.
19. Ames V, Britton PD Stereotactically guided breast biopsy: a review. Insights Imaging 2011, 2:171-176. 10.1007/s13244-010-0064-1.
20. Ioffe OB, Berg WA, Silverberg SG, Kumar D Mammographic-histopathologic correlation of large-core needle biopsies of the breast. Mod Pathol 1998, 11:721-727.
21. Boerner S, Sneige N Specimen adequacy and false-negative diagnosis rate in fine-needle aspirates of palpable breast masses. Cancer 1998, 84:344-348. [pii]. 10.1002/(SICI)1097-0142(19981225)84:6<344::AID-CNCR5>3.0.CO;2-R.
22. Ellis MJ, Dixon M, Dowsett M, Nagarajan R, Mardis E A luminal breast cancer genome atlas: progress and barriers. J Steroid Biochem Mol Biol 2007, 106:125-129. 10.1016/j.jsbmb.2007.05.011.
23. Gisvold JJ, Goellner JR, Grant CS, Donohue JH, Sykes MW, Karsell PR, Coffey SL, Jung SH Breast biopsy: a comparative study of stereotaxically guided core and excisional techniques. AJR Am J Roentgenol 1994, 162:815-820.
24. Oyama T, Koibuchi Y, McKee G Core needle biopsy (CNB) as a diagnostic method for breast lesions: comparison with fine needle aspiration cytology (FNA). Breast Cancer 2004, 11:339-342.
25. Retsky M, Demicheli R, Hrushesky WJ, Forget P, De Kock M, Gukas I, Rogers RA, Baum M, Sukhatme V, Vaidya JS Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. Curr Med Chem 2013, 20:4163-4176.
26. Demicheli R, Retsky MW, Hrushesky WJ, Baum M Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol 2007, 4:699-710. 10.1038/ncponc0999.
27. Hansen NM, Ye X, Grube BJ, Giuliano AE Manipulation of the primary breast tumor and the incidence of sentinel node metastases from invasive breast cancer. Arch Surg 2004, 139:634-639. [discussion 639-640]. 10.1001/archsurg.139.6.634.
28. Chao C, Torosian MH, Boraas MC, Sigurdson ER, Hoffman JP, Eisenberg BL, Fowble B Local recurrence of breast cancer in the stereotactic core needle biopsy site: case reports and review of the literature. Breast J 2001, 7:124-127.
29. Hofer SO, Shrayer D, Reichner JS, Hoekstra HJ, Wanebo HJ Wound-induced tumor progression: a probable role in recurrence after tumor resection. Arch Surg 1998, 133:383-389.
30. Coffey JC, Wang JH, Smith MJ, Bouchier-Hayes D, Cotter TG, Redmond HP Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 2003, 4:760-768.
31. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID The effects of surgery on tumor growth: a century of investigations. Ann Oncol 2008, 19:1821-1828. 10.1093/annonc/mdn386.
32. Al-Sahaf O, Wang JH, Browne TJ, Cotter TG, Redmond HP Surgical injury enhances the expression of genes that mediate breast cancer metastasis to the lung. Ann Surg 2010, 252:1037-1043. [pii]. 10.1097/SLA.0b013e3181efc635 00000658-201012000-00020.
33. Ben-Eliyahu S The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain Behav Immun 2003, 17(Suppl. 1):S27-S36.
34. Diaz LK, Wiley EL, Venta LA Are malignant cells displaced by large-gauge needle core biopsy of the breast?. AJR Am J Roentgenol 1999, 173:1303-1313.
35. Perez RO, Habr-Gama A, Proscurshim I, Campos FG, Kiss D, Gama-Rodrigues J, Cecconello I Local excision for ypT2 rectal cancer-much ado about something. J Gastrointest Surg 2007, 11:1431-1438. [discussion 1438-1440]. 10.1007/s11605-007-0271-3.
36. Chagpar AB, Scoggins CR, Sahoo S, Martin RC, Carlson DJ, Laidley AL, El-Eid SE, McGlothin TQ, Noyes RD, Ley PB, et al. Biopsy type does not influence sentinel lymph node status. Am J Surg 2005, 190:551-556. [S0002-9610(05)00543-X [pii]]. 10.1016/j.amjsurg.2005.06.009.
37. Knight R, Horiuchi K, Parker SH, Ratzer ER, Fenoglio ME Risk of needle-track seeding after diagnostic image-guided core needle biopsy in breast cancer. JSLS 2002, 6:207-209.
38. Liebens F, Carly B, Cusumano P, Van Beveren M, Beier B, Fastrez M, Rozenberg S Breast cancer seeding associated with core needle biopsies: a systematic review. Maturitas 2009, 62:113-123. 10.1016/j.maturitas.2008.12.002.
39. Diaz NM, Vrcel V, Centeno BA, Muro-Cacho C Modes of benign mechanical transport of breast epithelial cells to axillary lymph nodes. Adv Anat Pathol 2005, 12:7-9.
40. Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, Anderson RL, Deng J, Xu M, Briest S, Biragyn A Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res 2009, 69:5996-6004. [0008-5472.CAN-08-4619 [pii]]. 10.1158/0008-5472.CAN-08-4619.
41. Neeman E, Ben-Eliyahu S Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav Immun 2013, (30 Suppl.):S32-S40. 10.1016/j.bbi.2012.03.006.
42. Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, Meyer-Schaller N, Schubeler D, van Nimwegen E, Christofori G Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 2013, 23:768-783. 10.1016/j.ccr.2013.04.020.
43. Juratli MA, Sarimollaoglu M, Siegel ER, Nedosekin DA, Galanzha EI, Suen JY, Zharov VP Real-time monitoring of circulating tumor cell release during tumor manipulation using in vivo photoacoustic and fluorescent flow cytometry. Head Neck 2013, 10.1002/hed.23439.
44. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339:580-584. 10.1126/science.1228522.
45. O'Flaherty JD, Gray S, Richard D, Fennell D, O'Leary JJ, Blackhall FH, O'Byrne KJ Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer 2012, 76:19-25. 10.1016/j.lungcan.2011.10.018.
46. Predina J, Eruslanov E, Judy B, Kapoor V, Cheng G, Wang LC, Sun J, Moon EK, Fridlender ZG, Albelda S, et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci U S A 2013, 110:E415-E424. 10.1073/pnas.1211850110.
47. Gabrilovich DI, Nagaraj S Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174. 10.1038/nri2506.
48. Quail DF, Joyce JA Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013, 19:1423-1437. 10.1038/nm.3394.
49. Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat 2013, 140:13-21. 10.1007/s10549-013-2618-7.
50. Griffith JW, Sokol CL, Luster AD Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 2014, 32:659-702. 10.1146/annurev-immunol-032713-120145.
51. Fridlender ZG, Albelda SM Tumor-associated neutrophils: friend or foe?. Carcinogenesis 2012, 33:949-955. 10.1093/carcin/bgs123.
52. Ben-Baruch A The tumor-promoting flow of cells into, within and out of the tumor site: regulation by the inflammatory axis of TNFα and chemokines. Cancer Microenviron 2012, 5:151-164. 10.1007/s12307-011-0094-3.
53. Karavitis J, Hix LM, Shi YH, Schultz RF, Khazaie K, Zhang M Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. PLoS One 2012, 7:e46342. 10.1371/journal.pone.0046342.
54. Hayashida T, Jinno H, Kitagawa Y, Kitajima M Cooperation of cancer stem cell properties and epithelial-mesenchymal transition in the establishment of breast cancer metastasis. J Oncol 2011, 2011:591427. 10.1155/2011/591427.
55. Sasportas LS, Gambhir SS Imaging circulating tumor cells in freely moving awake small animals using a miniaturized intravital microscope. PLoS One 2014, 9:e86759. 10.1371/journal.pone.0086759.
56. Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol 2012, 17:96-104. 10.1007/s10147-011-0260-0.
57. DuPré SA, Redelman D, Hunter KW The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci. Int J Exp Pathol 2007, 88:351-360. 10.1111/j.1365-2613.2007.00539.x.
58. Younos I, Donkor M, Hoke T, Dafferner A, Samson H, Westphal S, Talmadge J Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells. Int Immunopharmacol 2011, 11:816-826. 10.1016/j.intimp.2011.02.021.
59. Foell D, Wittkowski H, Vogl T, Roth J S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007, 81:28-37. 10.1189/jlb.0306170.
60. Zhang J, Liang Q, Lei Y, Yao M, Li L, Gao X, Feng J, Zhang Y, Gao H, Liu DX, et al. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. Cancer Res 2012, 72:4597-4608. 10.1158/0008-5472.CAN-12-1045.
61. Schmidt M, Böhm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008, 68:5405-5413. 10.1158/0008-5472.CAN-07-5206.
62. Peach G, Kim C, Zacharakis E, Purkayastha S, Ziprin P Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer 2010, 102:1327-1334. 10.1038/sj.bjc.6605651.
63. Burgess DJ Breast cancer: circulating and dynamic EMT. Nat Rev Cancer 2013, 13:148. 10.1038/nrc3475.
64. Playfair JHL, Chain BM Immunology at a Glance 2009, Wiley-Blackwell, Chichester, United Kingdom; Hoboken, NJ. 9th edn.
65. Todd I, Spickett G Lecture notes. Immunology 2010, Wiley-Blackwell, Chichester, West Sussex; Hoboken, NJ. 6th edn.
66. Janeway's Immunobiology. Choice: Current Reviews for Academic Libraries 2008, 45:1793-1794.
67. Sompayrac L How the Immune System Works 2008, Blackwell Publishing, Malden, MA. 3rd edn.
68. Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, De Baetselier P, Van Ginderachter JA Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol 2011, 55:861-867. 10.1387/ijdb.113371dl.
69. Sica A Role of tumour-associated macrophages in cancer-related inflammation. Exp Oncol 2010, 32:153-158.
70. Mishalian I, Bayuh R, Eruslanov E, Michaeli J, Levy L, Zolotarov L, Singhal S, Albelda SM, Granot Z, Fridlender ZG Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17-a new mechanism of impaired antitumor immunity. Int J Cancer 2014, 10.1002/ijc.28770.
71. Hirbe AC, Morgan EA, Weilbaecher KN The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?. Curr Pharm Des 2010, 16:1284-1290. [DOI:BSP/CPD/E-Pub/00048 [pii]].
72. Huang M, Li Y, Zhang H, Nan F Breast cancer stromal fibroblasts promote the generation of CD44+CD24- cells through SDF-1/CXCR4 interaction. J Exp Clin Cancer Res 2010, 29:80. [1756-9966-29-80 [pii]]. 10.1186/1756-9966-29-80.
73. Kochetkova M, Kumar S, McColl SR Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ 2009, 16:664-673. [cdd2008190 [pii]]. 10.1038/cdd.2008.190.
74. Haas S, Park TW, Hahne JC, Fischer HP Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue. Virchows Arch 2008, 452:277-283. 10.1007/s00428-007-0563-8.
75. Kim SJ, Shiba E, Taguchi T, Watanabe T, Tanji Y, Kimoto Y, Izukura M, Takai SI Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer. Anticancer Res 1997, 17:1373-1378.
76. Conese M, Blasi F The urokinase/urokinase-receptor system and cancer invasion. Baillieres Clin Haematol 1995, 8:365-389.